Institute of Biomedical Technology, University of Tampere, and Tampere University Hospital, Tampere, Finland.
Nat Struct Mol Biol. 2011 Aug 14;18(9):971-6. doi: 10.1038/nsmb.2099.
Human JAK2 tyrosine kinase mediates signaling through numerous cytokine receptors. The JAK2 JH2 domain functions as a negative regulator and is presumed to be a catalytically inactive pseudokinase, but the mechanism(s) for its inhibition of JAK2 remains unknown. Mutations in JH2 lead to increased JAK2 activity, contributing to myeloproliferative neoplasms (MPNs). Here we show that JH2 is a dual-specificity protein kinase that phosphorylates two negative regulatory sites in JAK2: Ser523 and Tyr570. Inactivation of JH2 catalytic activity increased JAK2 basal activity and downstream signaling. Notably, different MPN mutations abrogated JH2 activity in cells, and in MPN (V617F) patient cells phosphorylation of Tyr570 was reduced, suggesting that loss of JH2 activity contributes to the pathogenesis of MPNs. These results identify the catalytic activity of JH2 as a previously unrecognized mechanism to control basal activity and signaling of JAK2.
人类 JAK2 酪氨酸激酶通过多种细胞因子受体介导信号转导。JAK2 JH2 结构域作为负调节剂发挥作用,被认为是一种无催化活性的假激酶,但它抑制 JAK2 的机制尚不清楚。JH2 中的突变导致 JAK2 活性增加,导致骨髓增殖性肿瘤(MPNs)。在这里,我们表明 JH2 是一种双特异性蛋白激酶,可磷酸化 JAK2 中的两个负调节位点:Ser523 和 Tyr570。JH2 催化活性的失活增加了 JAK2 的基础活性和下游信号转导。值得注意的是,不同的 MPN 突变使 JH2 在细胞中的活性丧失,并且在 MPN(V617F)患者细胞中 Tyr570 的磷酸化减少,表明 JH2 活性的丧失有助于 MPN 的发病机制。这些结果确定了 JH2 的催化活性是控制 JAK2 基础活性和信号转导的先前未被认识的机制。